MET and prostate carcinoma: We also demonstrated the effective degradation of c-MET by the AS1411-SL1 chimeras in a human prostate cancer cell line DU145 (DC50 for AS1411-SL1-2 and AS1411-SL1-3 was 237.4 nM and 287.8 nM, respectively), and a human cervical cancer cell line HeLa (DC50 for AS1411-SL1-2 and AS1411-SL1-3 was 575.2 nM and 337.1 nM, respectively) (Figure S2C-S2N).